SCHEMBL18520224

SCHEMBL18520224

Cc1cc(C)c2c(C(=O)NC3CC4CCC5CC4CC3C5)c[nH]c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNQ3 O43525 1/20 0.42
▸ KCNQ2 O43526 1/20 0.42
▸ KCNQ4 P56696 1/20 0.42
▸ KCNQ5 Q9NR82 1/20 0.42
▸ KDM4E B2RXH2 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ NPC1 O15118 2/20 0.38
▸ TAS1R3 Q7RTX0 3/20 0.37
▸ TAS1R1 Q7RTX1 3/20 0.37
▸ TAS1R2 Q8TE23 3/20 0.37
▸ LMNA P02545 3/20 0.37
▸ HTT P42858 3/20 0.37
▸ MAPT P10636 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ GRM1 Q13255 2/20 0.36
▸ CNR2 P34972 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17206300 0.81 CNR2 (0.42) KCNQ3KCNQ2KCNQ4KCNQ5ALDH1A1
SCHEMBL17206332 0.75 TAS1R3 (0.58) ALDH1A1HPGDNPC1TAS1R3TAS1R1
SCHEMBL17205222 0.75 TAS1R3 (0.58) ALDH1A1HPGDNPC1TAS1R3TAS1R1
SCHEMBL17209758 0.71 NR4A2 (0.41) KDM4EALDH1A1HSD17B10NPC1MAPT
SCHEMBL17206324 0.71 CNR2 (0.56) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL18183293 0.70 KCNQ3 (0.32) KCNQ3KCNQ2KCNQ4KCNQ5NPC1
SCHEMBL17209765 0.66 KDM4E (0.47) KDM4EHSD17B10LMNAMAPTRAB9A
SCHEMBL17205524 0.66 KDM4E (0.46) KDM4EMAPT
SCHEMBL13638925 0.64 HSD17B10 (0.70) KDM4EALDH1A1HSD17B10HPGDTSHR
SCHEMBL17205197 0.62 TAS1R3 (0.45) KCNQ3KCNQ2KCNQ4KCNQ5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170044100-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS UNIV JOHNS HOPKINS (US) 2017-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044100-A1 INHIBITORS OF DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS IDO2, IDO1, INMT KCNQ3 3862/4885KCNQ2 3582/4885KCNQ4 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback